Compare AGPU & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGPU | RANI |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 84.6M |
| IPO Year | 2008 | 2021 |
| Metric | AGPU | RANI |
|---|---|---|
| Price | $7.87 | $0.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 281.5K | ★ 527.3K |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | N/A | ★ N/A |
| Revenue | $125,284.00 | ★ $1,633,000.00 |
| Revenue This Year | $48,110.47 | $283.19 |
| Revenue Next Year | $614.07 | $5.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $1.03 | $0.57 |
| 52 Week High | $13.49 | $2.63 |
| Indicator | AGPU | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 34.74 | 31.61 |
| Support Level | $7.44 | N/A |
| Resistance Level | $9.30 | $0.85 |
| Average True Range (ATR) | 0.91 | 0.05 |
| MACD | -0.35 | -0.02 |
| Stochastic Oscillator | 6.96 | 12.79 |
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.